Multiple Myeloma Clinical Trial
Official title:
A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the efficacy of lenalidomide plus low-dose
dexamethasone in Chinese subjects with relapsed or refractory multiple myeloma.
Even though the efficacy and safety of lenalidomide has already been well-demonstrated in
other populations including Asians, this study will assess the efficacy and safety as well as
pharmacokinetics of lenalidomide in Chinese subjects. In addition, this study will generate
clinically meaningful information in guiding the therapeutic use of lenalidomide for Chinese
subjects.
This is a Phase II, multicenter, single arm, open-label trial which will enroll Chinese
subjects in China with relapsed/refractory multiple myeloma that will assess the efficacy and
safety of lenalidomide plus low-dose dexamethasone regimen (Rd) given until progressive
disease (PD) or discontinuation of lenalidomide for any reason.
There are two cohorts in this protocol, Pharmacokinetic Assessment Treatment Cohort and
Treatment Cohort without Pharmacokinetic (PK) Assessment. The first 10 subjects who are ≤ 75
years old and have a baseline Creatinine Clearance ≥ 60 mL/min will participate in
pharmacokinetic assessment during the first 8 days of Cycle 1. During this cohort, all
subjects will receive 25mg oral lenalidomide once daily on days 1 -21 of each 28-day cycle.
During the first cycle of this cohort, subjects will also receive 40mg oral dexamethasone
daily on Days 8, 15, and 22 (and no dexamethasone on day 1). Beginning with Cycle 2, subjects
will receive 25mg oral lenalidomide once daily on days 1 -21 of each 28-day cycle and 40mg
oral dexamethasone daily on Days 1, 8, 15 and 22 of each 28-day cycle.
Once 10 subjects have been enrolled in the PK Assessment Treatment Cohort, the Treatment
Cohort without PK Assessment will begin. During this cohort, subjects will receive
lenalidomide 25 mg p.o. once daily on Days 1-21 and dexamethasone 40 mg p.o. once daily on
Days 1, 8, 15, and 22 of each 28-day cycle. In both cohorts, subjects will continue Rd
therapy until the documentation of PD or discontinuation of study therapy due to any reason
including intolerable toxicity.
For the primary analysis, response will be assessed according to the European Group for Blood
and Marrow Transplantation EBMT (Bladé) criteria by an Independent Response Adjudication
Committee (IRAC). Response will also be assessed according to the International Myeloma
Working Group (IMWG) criteria and used as an exploratory analysis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |